Equities Analysts Set Expectations for Bruker Q1 Earnings

Bruker Co. (NASDAQ:BRKR - Free Report) - Analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for shares of Bruker in a research note issued to investors on Monday, February 10th. Zacks Research analyst R. Department now expects that the medical research company will earn $0.83 per share for the quarter, down from their previous forecast of $0.86. The consensus estimate for Bruker's current full-year earnings is $2.40 per share.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 9.41% and a return on equity of 21.52%.

Several other equities analysts have also commented on BRKR. TD Cowen lowered their price objective on shares of Bruker from $72.00 to $70.00 and set a "hold" rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group raised shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target for the company in a report on Thursday, December 5th. Barclays reduced their price objective on Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research note on Friday, January 17th. Finally, Bank of America increased their price target on Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a report on Friday, December 13th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Bruker currently has an average rating of "Moderate Buy" and a consensus target price of $70.50.

Bruker Price Performance

NASDAQ:BRKR traded down $1.11 during trading hours on Thursday, reaching $50.04. The stock had a trading volume of 2,044,498 shares, compared to its average volume of 1,412,424. The company has a 50 day moving average price of $57.56 and a two-hundred day moving average price of $60.48. Bruker has a 52 week low of $48.07 and a 52 week high of $94.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. The stock has a market capitalization of $7.59 billion, a PE ratio of 24.06, a PEG ratio of 3.81 and a beta of 1.16.

Institutional Trading of Bruker

Several institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC increased its position in shares of Bruker by 21.4% during the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock worth $987,981,000 after purchasing an additional 2,521,904 shares in the last quarter. London Co. of Virginia grew its stake in shares of Bruker by 78.4% during the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after acquiring an additional 1,843,294 shares during the last quarter. FIL Ltd increased its holdings in shares of Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock valued at $114,978,000 after acquiring an additional 1,420,102 shares in the last quarter. Norges Bank purchased a new position in shares of Bruker in the 4th quarter valued at approximately $63,378,000. Finally, Marshall Wace LLP boosted its stake in Bruker by 4,510.3% in the 4th quarter. Marshall Wace LLP now owns 783,988 shares of the medical research company's stock worth $45,957,000 after purchasing an additional 766,983 shares in the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.